NCT04815720
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04815720
Title Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84)
Acronym KEYNOTE-B84
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Vaccinex Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Highlands Oncology Group, PA - North Hills Springdale Arkansas 72762 United States Details
California Cancer Associates for Research and Excellence (CCARE)-Fresno Fresno California 93720 United States Details
UCSF Medical Center at Mission Bay San Francisco California 94158 United States Details
Yale Cancer Center New Haven Connecticut 06510 United States Details
AdventHealth Celebration Celebration Florida 34747 United States Details
AdventHealth Orlando Orlando Florida 32803 United States Details
Emory Saint Joseph's Hospital Atlanta Georgia 30308 United States Details
American Oncology Partners of Maryland, PA Bethesda Maryland 20817 United States Details
Siteman Cancer Center - Washington University Medical Campus St Louis Missouri 63110 United States Details
Northwell Health - Centers for Advanced Medicine Lake Success New York 11042 United States Details
University of Rochester Rochester New York 14642 United States Details
Messino Cancer Centers Asheville North Carolina 28806 United States Details
Gabrail Cancer Research Center Canton Ohio 44718 United States Details
Allegheny General Hospital Pittsburgh Pennsylvania 15212 United States Details
Virginia Cancer Specialists - Fairfax Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field